ABDD HABP/VABP Studies

Expert Meetings

Overview

Clinical trials of new antibacterial drugs for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) are critically needed but challenging to conduct.  

Building on our streamlining HABP/VABP trials work, CTTI conducted a prospective, multi-center, observational study of the risk factors for HABP/VABP, with over 6,700 adult patients enrolled at 28 U.S. sites and seven European sites, and 800 pediatric patients enrolled at nine U.S. children’s hospitals. 

The study, an analysis of cost drivers and formative research on an early consent approach, are informing resources to help you develop and streamline HABP/VABP clinical trial planning.  For example, patients at high risk for developing pneumonia could be approached and consented early, potentially before pneumonia symptoms develop so that fewer patients are excluded because they have already received 24 hours of effective antibacterial therapy. 

Solutions

Search All

News

Case Study

    In Detail